ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them

Marc Kennis Marc Kennis, May 1, 2023

ASX Life Sciences stocks are back, baby!

ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.

The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.

He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).


ASX Life Science stocks

Stuart Roberts on AusBiz talking ASX Life Sciences stocks


Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.




There’s no credit card needed – the trial expires automatically.




Blog Categories

Recent Posts

Hydrogen Production Credit

Australia’s $2 Billion Hydrogen Production Credit: What It Means for the Green Energy Sector

In the Federal Budget for 2024-25, the Australian Government introduced a transformative $2 billion hydrogen production credit. This bold initiative…

Most common Rare Earths

Here are 3 of the most common rare earths and the ASX stocks exposed to them

In this article, we recap some of the most common rare earths (not so rare earths) and some of the…


What is CAGR and why do listed companies like using it?

Although it is not as commonly used by ASX-listed companies, Compound annual growth rate (CAGR), is a growth metric you’ll…